Physician profile
Magy Labib
NPI 1629787015
$4,664.99
in general payments reported to CMS, 2019-2025
25 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $1,649 · 2024: $1,827 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $844.03 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Corium, LLC | $511.91 | 2022-2025 | Azstarys |
| Abbvie INC. | $403.34 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.36 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $376.24 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $321.54 | 2022-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $297.38 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $255.44 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $229.79 | 2022-2025 | Aristada, Lybalvi |
| Validus Pharmaceuticals LLC | $163.80 | 2023-2024 | Equetro |
| Janssen Pharmaceuticals, INC | $142.14 | 2022-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $115.98 | 2022-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $86.72 | 2023-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $74.20 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $63.33 | 2023-2024 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $60.33 | 2023-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $53.81 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $53.56 | 2023-2024 | |
| Noven Therapeutics, LLC | $50.43 | 2023-2024 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $46.49 | 2025 | Qelbree |
| Tris Pharma INC | $32.76 | 2024-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $31.33 | 2023 | Belsomra |
| Avadel Cns Pharmaceuticals, LLC | $29.68 | 2023-2024 | Lumryz |
| Almatica Pharma LLC | $29.01 | 2023 | Loreev Xr, Sertraline Hcl |
| Collegium Pharmaceutical, INC. | $15.39 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magy Labib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.